Background: Basal cell carcinoma (BCC) represents the most common nonmelanoma skin cancer worldwide, affecting mainly adult, fair-skinned individuals. The World Health Organization distinguishes aggressive and nonaggressive forms, of which prototypical variants of the latter are primary nodular and superficial BCC.
Objectives: To demonstrate noninferiority of BF-200 ALA (a nanoemulsion gel containing 5-aminolaevulinic acid) compared with MAL (a cream containing methyl aminolaevulinate) in the treatment of nonaggressive BCC with photodynamic therapy (PDT). Noninferiority of the primary efficacy variable (overall patient complete response 12 weeks after last PDT) would be declared if the mean response for BF-200 ALA was no worse than that for MAL, within a statistical margin of Δ = -15%.
Methods: The study was a randomized, phase III trial performed in Germany and the U.K. with ongoing 5-year follow-up. Of 281 randomized patients, 138 were treated with BF-200 ALA and 143 with MAL. Patients received two PDT sessions 1 week apart. Remaining lesions 12 weeks after the second PDT were retreated. Illumination was performed with a red light source (635 nm, 37 J cm ). The results shown include clinical end points and patients' reassessment 12 months after the last PDT. The study was registered with EudraCT (number 2013-003241-42).
Results: Of the BF-200 ALA-treated patients, 93·4% were complete responders compared with 91·8% in the MAL group. The difference of means was 1·6, with a one-sided 97·5% confidence interval of -6·5, establishing noninferiority (P < 0·0001). The results for secondary efficacy parameters were in line with the primary outcome. Recurrence rates 12 months after the last treatment were ≤ 10%.
Conclusions: Treatment of nonaggressive BCC with BF-200 ALA-PDT is highly effective and well tolerated with proven noninferiority to MAL-PDT. It demonstrates low recurrence rates after 1 year of follow-up.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bjd.16441 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early recurrence after surgery in FIGO 2023 stage I-III endometrial cancer: characteristics and risk factors.
Front Oncol
January 2025
Department of Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Background: Understanding the risk factors for early recurrence is crucial for improving endometrial cancer (EC) patient outcomes.
Methods: We conducted a retrospective analysis of clinicopathological data from 473 patients diagnosed with EC at the First Affiliated Hospital of Chongqing Medical University between October 2013 and May 2019. We evaluated factors influencing early recurrence(defined as occurring within 12 months after treatment) based on 2023 International Federation of Gynecology and Obstetrics (FIGO) staging system.
Pharmacological Vitamin C-induced high HO generation mediates apoptotic cell death by caspase 3/7 activation in breast cancer tumor spheroids.
J Transl Med
January 2025
Department of Haematology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, 16150, Kelantan, Malaysia.
Background: Pharmacological vitamin C (Vit-C), or high-dose Vit-C has recently gained attention as a potential cancer therapeutic. However, the anticancer activity of Vit-C has not been investigated in realistic 3D models of human cancers, especially with respect to breast cancer (BC), and its potential benefits remain under debate. Herein, we investigate the activity and mechanism of action of pharmacological Vit-C on two BC tumor spheroids.
View Article and Find Full Text PDFHigh correlation between Ki-67 expression and a novel perfusion MRI biomarker diffusion-derived vessel density (DDVD) in endometrial carcinoma.
Magn Reson Imaging
January 2025
Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy Tianjin, Tianjin, China. Electronic address:
Objective: This study aimed to investigate the feasibility of diffusion-derived vessel density (DDVD) in characterizing tumor microvasculature in endometrial carcinoma (EC), and to explore the correlations with Ki-67 proliferation status and histological type based on DDVD values.
Methods: There were in total 81 EC patients. There were 64 cases of non-aggressive histological type, and 17 cases of aggressive histological type.
Deep learning for endometrial cancer subtyping and predicting tumor mutational burden from histopathological slides.
NPJ Precis Oncol
December 2024
Institute of Pathology and Parasitology, National Defense Medical Center, Taipei, Taiwan.
Endometrial cancer (EC) diagnosis traditionally relies on tumor morphology and nuclear grade, but personalized therapy demands a deeper understanding of tumor mutational burden (TMB), i.e., a key biomarker for immune checkpoint inhibition and immunotherapy response.
View Article and Find Full Text PDFProtocol for a randomized controlled trial of strength at home in Israel: A trauma informed intervention for intimate partner violence based on a social-information processing model.
Contemp Clin Trials
December 2024
National Center for PTSD, VA Boston Healthcare System, and Boston University Chobanian and Avedisian School of Medicine, USA. Electronic address:
Background: The social information processing (SIP) model of trauma and intimate partner violence (IPV), which emphasizes the impact of trauma on one's ability to accurately process social information and subsequent failure to generate and enact nonaggressive responses, has gained attention in the United States. Recent clinical trial evidence suggests that the Strength at Home (SAH) intervention, a 12-session program that is based on this model, is efficacious in reducing and ending abusive behavior among U.S.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!